Simmunome is betting that the future of drug discovery isn't in the wet lab—it's in the simulation. With a lean team of 13 and a proprietary generative AI platform, they're mechanistically modeling how drug targets behave in the human body, potentially cutting years off R&D timelines.

"They're not just predicting drug efficacy—they're simulating the entire mechanistic pathway to see what happens before a single molecule is synthesized."

What makes Simmunome unique is their hybrid approach: combining mechanistic modeling with machine learning. Most AI drug discovery platforms rely purely on statistical pattern recognition. Simmunome adds the 'why'—the biological mechanism—potentially making their predictions more reliable for safety and efficacy.

• Mechanistic + ML hybrid approach for higher accuracy
• Generative AI platform for target validation
• Focus on efficacy AND safety prediction
• Enterprise-focused, not consumer-facing
• Early-stage but revenue-generating